Patrick Burnett - 11 Aug 2026 Form 4 Insider Report for Arcutis Biotherapeutics, Inc. (ARQT)

Reporting relationship: Reporting Person's title: EVP, Chief Medical Officer
Issuer ticker: ARQT
Reported as of: 11 Aug 2026
Net transaction value: -$394,897
SEC form: 4
Accepted by SEC: 13 Aug 2026, 20:06:49 UTC
Prior SEC filing: 05 Aug 2026
Next SEC filing: 21 Aug 2026
Source filing: View source filing
Reporting owner signature: /s/ Latha Vairavan, as Attorney-in-Fact for Patrick Burnett

Key filing fact

Patrick Burnett filed Form 4 for Arcutis Biotherapeutics, Inc. (ARQT) on 13 Aug 2026.

Key facts

This page summarizes Patrick Burnett's Form 4 filing for Arcutis Biotherapeutics, Inc. (ARQT).
6 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 13 Aug 2026, 20:06.

Change

Previous filing in this sequence was filed on 05 Aug 2026.
Current net transaction value: -$394,897.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001741987 Primary reporting owner

Burnett Patrick

Relationship: Reporting Person's title: EVP, Chief Medical Officer
Address: C/O ARCUTIS BIOTHERAPEUTICS, INC., 3027 TOWNSGATE ROAD, SUITE 300, WESTLAKE VILLAGE
Signature: /s/ Latha Vairavan, as Attorney-in-Fact for Patrick Burnett
Signature date: 13 Aug 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ARQT transaction

Common Stock

Options Exercise

Transaction value
Shares: +8,300
Change %: +7%
Price: $3.64^*
Shares after: 127,589
Date: 11 Aug 2026
Ownership: Direct
Footnotes: F1

ARQT transaction

Common Stock

Sale

Transaction value: $220,129
Shares: -8,300
Change %: -6.5%
Price: $26.52
Shares after: 119,289
Date: 11 Aug 2026
Ownership: Direct
Footnotes: F1, F2

ARQT transaction

Common Stock

Options Exercise

Transaction value
Shares: +6,700
Change %: +5.6%
Price: $3.64^*
Shares after: 125,989
Date: 12 Aug 2026
Ownership: Direct
Footnotes: F1

ARQT transaction

Common Stock

Sale

Transaction value: $174,767
Shares: -6,700
Change %: -5.3%
Price: $26.08
Shares after: 119,289
Date: 12 Aug 2026
Ownership: Direct
Footnotes: F1, F3

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ARQT transaction Derivative

Stock Option (right to buy)

Options Exercise

Transaction value
Shares: -8,300
Change %: -5.8%
Price: $0.000000^*
Shares after: 135,450
Date: 11 Aug 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 8,300
Exercise price: $3.64
Footnotes: F1

ARQT transaction Derivative

Stock Option (right to buy)

Options Exercise

Transaction value
Shares: -6,700
Change %: -4.9%
Price: $0.000000^*
Shares after: 128,750
Date: 12 Aug 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 6,700
Exercise price: $3.64
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

On January 12, 2024, the Reporting Person was granted options, in which 1/48th of the shares subject to the option vest on each monthly anniversary measured from January 12, 2024 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer.

Footnote F2

The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $26.50 to $26.57, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

Footnote F3

The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $26.00 to $26.19, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

SEC remarks

Reporting Person's title: EVP, Chief Medical Officer